Published: March 06, 2011
China Medical System Accredited in 'China's Top 100 Potential Enterprises' by Forbes China for Two Consecutive Years
Hong Kong, Mar 7, 2011 - (ACN Newswire) - China Medical System Holdings Limited ("CMS" or the "Company", SEHK: 867), a leading China-based pharmaceutical services company focusing on the marketing, promotion and sale of prescription drugs, is pleased to announce that the Company was accredited as "China's Top 100 Potential Enterprises" among the list compiled by the Forbes China in February 2011. CMS has been selected on the list for two consecutive years.
Compiled by Forbes China, the "China's Top 100 Potential Enterprises" list focuses on the SMEs in China, and is the first ranking of its kind to cover the SMEs across all industries. This is the second consecutive year that CMS has won the coveted accolade for its outstanding business performance and contribution to the development of China's SMEs, and for its efforts to strive for excellence in its field.
About "China's Top 100 Potential Enterprises" by Forbes China
http://www.forbeschina.com/list/1008/more
About CMS
China Medical System Holdings Limited ("CMS", together with its subsidiaries, the "Group") is a leading provider of marketing, promotion and sales services for prescription drugs in China. The Group was established in 1995, and was listed on AIM in London (ticker: CMSH) in June 2007. The group successfully listed on the Main Board of Hong Kong Stock Exchange on 28 September 2010 (Stock code: 867), on the same day the company canceled the trading of its shares on AIM in London. CMS has the largest third-party promotion network in China in terms of hospital coverage, therapeutic focus and number of sales people. As of 31 December 2010, CMS has over 970 staff in its marketing, promotion and sales team, reaches close to 7,000 hospitals located across 31 provinces and over 120,000 target physicians in China, and at the present, CMS is marketing 9 main products in China which cover several therapeutic areas including the neurology, psychiatry, hepatology, gastroenterology, infectious diseases, urology, ophthalmology, cardiovascular disease, pediatrics and oncology. With deep insight and understanding of the Chinese pharmaceutical market, available treatment options, patient demography and potential competitive advantages of drugs, CMS will continue to focus on new product introduction and expand its sales network to consolidate and promote its leading position in the pharmaceutical services market in China.
For more information, please visit the Company website at www.cms.net.cn.
Source: CMS
Contact:
Hill and Knowlton Asia Ltd.
Crystal Yip
Tel: +852 2894 6211 / 9720 6445
Email: crystal.yip@hillandknowlton.com.hk
James Wong
Tel: +852 2894 6216 / 9300 2263
Email: james.wong@hillandknowlton.com.hk
Search News
